

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8281784

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	07/10/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	DR SATHIBALAN PONNIAH
<b>Street Address:</b>	7008 GOLDEN SEEDS ROW
<b>City:</b>	COLUMBIA
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	21044
<b>PROPERTY NUMBERS Total: 5</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	9370560
<b>Patent Number:</b>	8222214
<b>Patent Number:</b>	8796220
<b>Patent Number:</b>	10842856
<b>Application Number:</b>	17574178
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(703)997-4905
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	7039170000
<b>Email:</b>	swilliams@mh2law.com, docketing@mh2law.com
<b>Correspondent Name:</b>	MH2 TECHNOLOGY LAW GROUP, LLP
<b>Address Line 1:</b>	1951 KIDWELL DRIVE
<b>Address Line 2:</b>	SUITE 310
<b>Address Line 4:</b>	TYSONS CORNER, VIRGINIA 22182
<b>ATTORNEY DOCKET NUMBER:</b>	HMJ-189-US
<b>NAME OF SUBMITTER:</b>	SHULING LAU WILLIAMS
<b>SIGNATURE:</b>	/Shuling Lau Williams/
<b>DATE SIGNED:</b>	11/16/2023
<b>Total Attachments: 7</b>	

source=HJF 157-07 Assignment - HJF to Ponniah\_FE#page1.tif  
source=HJF 157-07 Assignment - HJF to Ponniah\_FE#page2.tif  
source=HJF 157-07 Assignment - HJF to Ponniah\_FE#page3.tif  
source=HJF 157-07 Assignment - HJF to Ponniah\_FE#page4.tif  
source=HJF 157-07 Assignment - HJF to Ponniah\_FE#page5.tif  
source=HJF 157-07 Assignment - HJF to Ponniah\_FE#page6.tif  
source=HJF 157-07 Assignment - HJF to Ponniah\_FE#page7.tif

**ASSIGNMENT**

WHEREAS, The Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., a 501(c)(3) nonprofit organization, with its principal offices at the time of execution of this document located at 1401 Rockville Pike, Suite 600, Rockville, Maryland 20852 (hereinafter “**ASSIGNOR**”) and Sathibalan Ponniah having a mailing address located at 7008 Golden Seeds Row, Columbia, Maryland 21044 (hereinafter “**ASSIGNEE**”) both have a history with certain intellectual property rights entitled Vaccine For The Prevention Of Breast Cancer Relapse (hereinafter, “**INVENTION**”) as set out in **EXHIBIT A**;

WHEREAS, ASSIGNEE, by virtue of being an inventor had right, title, and interest to this INVENTION;

WHEREAS, ASSIGNEE conveyed their entire right, title, and interest in and to this INVENTION by virtue of an assignment executed by on January 27, 2009, in favor of ASSIGNOR;

WHEREAS, ASSIGNOR by virtue of an assignment from Uniformed Services University of the Health Sciences executed on April 15, 2009, together with the January 27, 2009, assignment from ASSIGNEE, once owned the entire right, title, and interest in and to this INVENTION;

WHEREAS, ASSIGNOR exclusively licensed the INVENTION to RXI Pharmaceuticals Corporation, effective July 11, 2011;

WHEREAS, that exclusive license was terminated effective May 11, 2023, by Sellas Life Sciences Group, Inc., the successor in interest to RXI Pharmaceuticals;

WHEREAS, by virtue of the termination of that exclusive license, ASSIGNOR currently owns the entire right, title, and interest in and to this INVENTION;

WHEREAS, ASSIGNEE is desirous of securing once again their share of the right, title, and interest in and to this INVENTION in all countries throughout the world, and in and to all applications for patents filed in all countries throughout the world on this INVENTION, and in and to all Letters Patent to be issued for this INVENTION throughout the world; AND

WHEREAS, ASSIGNOR is willing to convey back to ASSIGNEE an undivided one-half interest in the right, title, and interest in and to this INVENTION currently owned by ASSIGNOR while acknowledging a concurrent assignment of an undivided one-half interest in the right, title, and interest in and to this INVENTION to Uniformed Services University of the Health Sciences;

NOW, THEREFORE, be it known that, for good and valuable consideration the receipt of which from ASSIGNEE is hereby acknowledged, I/We, as ASSIGNOR, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the ASSIGNEE, its lawful successors and assigns, an undivided one-half interest in my/our right, title, and interest in and to this INVENTION and all related application(s) or Letters Patent(s) (as set out in **EXHIBIT A**), and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority on the basis of any of these related application(s) or Letters Patent(s) (as set out in **EXHIBIT A**), and all applications for Letters Patent which may hereafter be filed for this INVENTION in any foreign country and all Letters Patent which may be granted on this INVENTION in any foreign country, and all extensions, renewals, and reissues thereof;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with ASSIGNEE, its successors and assigns, any facts known to me/us respecting this INVENTION, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this INVENTION in said ASSIGNEE, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid ASSIGNEE, its successors and assigns, to obtain and enforce proper patent protection for this INVENTION in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the ASSIGNEE, its successors and assigns;


AND I/WE HEREBY authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this INVENTION to ASSIGNEE, its successors and assigns, in accordance with the terms of this Assignment;

AND I/WE HEREBY authorize and request my/our agents, MH2 Technology Law Group LLP, whose address is 1951 Kidwell Drive, Suite 310, Tysons Corner, VA 22182, to insert hereon any identification necessary or desirable for recordation of this document, including the filing date and application number of said application when known.


[Signature Page to Follow]


IN WITNESS WHEREOF the ASSIGNOR, by the hand of an authorized representative, and ASSIGNEE have signed this Assignment and the ASSIGNEE acknowledges receipt of all rights conveyed by this Assignment.

By: **The Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.**  
(ASSIGNOR).

By:   
Name: La Shaun Berrien, Ph.D.  
Title: Vice President, Research Administration  
and Innovation Management  
Date: July 10, 2023

Subscribed and sworn to before me this  
10 day of July, 2023

  
Notary Public



SEAL


By: **Dr. Sathibalan Ponniah (ASSIGNEE),**

By: S. P. P.  
Name: Sathibalan Ponniah  
Title: Scientist  
Date: 9/14/2023

Subscribed and sworn to before me this

14 day of September, 2023

[Signature]  
Notary Public



SEAL

**EXHIBIT A**

HIF 157-07 AT	2162149	AT	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 AU	2008260399	AU	Issued	7/10/2014	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 AU2	2014201488	AU	Issued	10/13/2016	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 BE	2162149	BE	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 BG	2162149	BG	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 CA	2,687,368	CA	Issued	10/30/2018	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 CH	2162149	CH	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 CY	2162149	CY	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 CZ	2162149	CZ	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 DE	602008028565.0	DE	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 DK	2162149	DK	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 EE	2162149	EE	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 ES	2162149	ES	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 FI	2162149	FI	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 FR	2162149	FR	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 GB	2162149	GB	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 GR	2162149	GR	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 HR	2162149	HR	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 HU	2162149	HU	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 IE	2162149	IE	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 IS	2162149	IS	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 IT	2162149	IT	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 JP	5635399	JP	Issued	10/24/2014	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 JP2	6097724	JP	Issued	2/24/2017	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 JP4	7072467	JP	Issued	5/12/2022	Vaccine for the Prevention of Breast Cancer Relapse
HIF 157-07 KR	10-1572474	KR	Issued	11/23/2015	Vaccine for the Prevention of Breast Cancer Relapse

HJF 157-07 KR2	10-1863534	KR	Issued	5/28/2018	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 KR4	10-2020-7004398	KR	Issued	7/26/2021	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 LJ	2162149	LJ	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 LT	2162149	LT	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 LU	2162149	LU	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 LV	2162149	LV	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 MC	2162149	MC	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 MT	2162149	MT	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 MX	294175	MX	Issued	1/3/2012	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 NL	2162149	NL	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 NO	2162149	NO	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 PL	2162149	PL	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 PT	2162149	PT	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 RO	2162149	RO	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 SE	2162149	SE	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 SI	2162149	SI	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 SK	2162149	SK	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 TR	2162149	TR	Issued	11/6/2013	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 US	8,222,214	US	Issued	7/17/2012	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 US2	8,796,220	US	Issued	8/5/2014	Vaccine for the Prevention of the Recurrence of HER2/neu Expressing Cancer
HJF 157-07 US3	9,370,560	US	Issued	6/21/2016	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 US7	10,842,856	US	Issued	11/4/2020	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 CN	200880018401.2	CN	Pending		Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 CN2	201610201242.6	CN	Pending		Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 EP2	13191663.7	EP	Pending		Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 HK	14110360.5	HK	Pending		Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 JP6	2022-068170	JP	Pending		Vaccine for the Prevention of Breast Cancer Relapse



HJF 157-07 KMR3	10-2018-7014920	K.R	Pending	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 US10	17/574,178	US	Pending	Vaccine for the Prevention of Breast Cancer Relapse
HJF 157-07 KRS	10-2021-7023573	K.R	Pending	Vaccine for the Prevention of Breast Cancer Relapse